Uric acid and long-term outcomes in CKD
- PMID: 19303683
- PMCID: PMC2691553
- DOI: 10.1053/j.ajkd.2008.12.021
Uric acid and long-term outcomes in CKD
Abstract
Background: Hyperuricemia is prevalent in patients with chronic kidney disease (CKD); however, data are limited about the relationship of uric acid levels with long-term outcomes in this patient population.
Study design: Cohort study.
Setting & participants: The Modification of Diet in Renal Disease (MDRD) Study was a randomized controlled trial (N = 840) conducted from 1989 to 1993 to examine the effects of strict blood pressure control and dietary protein restriction on progression of stages 3 to 4 CKD. This analysis included 838 patients.
Predictor: Uric acid level.
Outcomes & measurements: The study evaluated the association of baseline uric acid levels with all-cause mortality, cardiovascular disease (CVD) mortality, and kidney failure.
Results: Mean age was 52 +/- 12 (SD) years, glomerular filtration rate was 33 +/- 12 mL/min/1.73 m(2), and uric acid level was 7.63 +/- 1.66 mg/dL. During a median follow-up of 10 years, 208 (25%) participants died of any cause, 127 (15%) died of CVD, and 553 (66%) reached kidney failure. In multivariate models, the highest tertile of uric acid was associated with increased risk of all-cause mortality (hazard ratio [HR], 1.57; 95% confidence interval [CI], 1.07 to 2.32), a trend toward CVD mortality (HR, 1.47; 95% CI, 0.90 to 2.39), and no association with kidney failure (HR, 1.20; 95% CI, 0.95 to 1.51) compared with the lowest tertile. In continuous analyses, a 1-mg/dL greater uric acid level was associated with 17% increased risk of all-cause mortality (HR, 1.17; 95% CI, 1.05 to 1.30) and 16% increased risk of CVD mortality (HR, 1.16; 95% CI, 1.01 to 1.33), but was not associated with kidney failure (HR, 1.02; 95% CI, 0.97 to 1.07).
Limitations: Primary analyses were based on a single measurement of uric acid. Results are generalizable primarily to relatively young white patients with predominantly nondiabetic CKD.
Conclusions: In patients with stages 3 to 4 CKD, hyperuricemia appears to be an independent risk factor for all-cause and CVD mortality, but not kidney failure.
Figures
Comment in
-
Uric acid, cardiovascular mortality, and long-term outcomes in CKD.Am J Kidney Dis. 2009 Sep;54(3):582; author reply 582-3. doi: 10.1053/j.ajkd.2009.06.024. Am J Kidney Dis. 2009. PMID: 19700064 No abstract available.
Similar articles
-
Serum uric acid levels and long-term outcomes in chronic kidney disease.Heart Vessels. 2014 Jul;29(4):504-12. doi: 10.1007/s00380-013-0396-0. Epub 2013 Aug 9. Heart Vessels. 2014. PMID: 23929090
-
Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD.Am J Kidney Dis. 2018 Mar;71(3):362-370. doi: 10.1053/j.ajkd.2017.08.017. Epub 2017 Nov 11. Am J Kidney Dis. 2018. PMID: 29132945 Free PMC article.
-
Serum bicarbonate and long-term outcomes in CKD.Am J Kidney Dis. 2010 Nov;56(5):907-14. doi: 10.1053/j.ajkd.2010.03.023. Epub 2010 Jun 3. Am J Kidney Dis. 2010. PMID: 20605301 Clinical Trial.
-
Serum uric acid and risk of cardiovascular mortality: a systematic review and dose-response meta-analysis of cohort studies of over a million participants.BMC Cardiovasc Disord. 2019 Oct 15;19(1):218. doi: 10.1186/s12872-019-1215-z. BMC Cardiovasc Disord. 2019. PMID: 31615412 Free PMC article.
-
New insights into uric acid effects on the progression and prognosis of chronic kidney disease.Ren Fail. 2012;34(4):510-20. doi: 10.3109/0886022X.2011.653753. Epub 2012 Jan 20. Ren Fail. 2012. PMID: 22260409 Review.
Cited by
-
Hyperuricemia in Kidney Disease: A Major Risk Factor for Cardiovascular Events, Vascular Calcification, and Renal Damage.Semin Nephrol. 2020 Nov;40(6):574-585. doi: 10.1016/j.semnephrol.2020.12.004. Semin Nephrol. 2020. PMID: 33678312 Free PMC article. Review.
-
Experimental and clinical nephroprotection by the xanthine oxidase inhibitor febuxostat.Naunyn Schmiedebergs Arch Pharmacol. 2016 Aug;389(8):815-7. doi: 10.1007/s00210-016-1260-4. Epub 2016 May 25. Naunyn Schmiedebergs Arch Pharmacol. 2016. PMID: 27220331 No abstract available.
-
Association between urinary uric acid excretion and kidney outcome in patients with CKD.Sci Rep. 2024 Mar 1;14(1):5119. doi: 10.1038/s41598-024-55809-9. Sci Rep. 2024. PMID: 38429496 Free PMC article.
-
A systematic review and meta-analysis of the association between uric acid levels and chronic kidney disease.Sci Rep. 2022 Apr 15;12(1):6251. doi: 10.1038/s41598-022-10118-x. Sci Rep. 2022. PMID: 35428828 Free PMC article.
-
Cystatin C as a predictor of mortality and cardiovascular events in a population with chronic kidney disease.Int J Nephrol. 2014;2014:127943. doi: 10.1155/2014/127943. Epub 2014 Feb 11. Int J Nephrol. 2014. PMID: 24672725 Free PMC article.
References
-
- Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand . 224:549–555. - PubMed
-
- Casiglia E, Spolaore P, Ginocchio G, Colangeli G, Di Menza G, Marchioro M, Mazza A, Ambrosio GB. Predictors of mortality in very old subjects aged 80 years or over. Eur J Epidemiol . 9:577–586. - PubMed
-
- Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. Jama . 283:2404–2410. - PubMed
-
- Liese AD, Hense HW, Lowel H, Doring A, Tietze M, Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology . 10:391–397. - PubMed
-
- Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med . 131:7–13. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical